BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31441116)

  • 21. Resveratrol analogue (E)-8-acetoxy-2-[2-(3,4-diacetoxyphenyl)ethenyl]-quinazoline induces G₂/M cell cycle arrest through the activation of ATM/ATR in human cervical carcinoma HeLa cells.
    Kim JY; Choi HE; Lee HH; Shin JS; Shin DH; Choi JH; Lee YS; Lee KT
    Oncol Rep; 2015 May; 33(5):2639-47. PubMed ID: 25812484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Withaferin A-induced apoptosis in human breast cancer cells is associated with suppression of inhibitor of apoptosis family protein expression.
    Hahm ER; Singh SV
    Cancer Lett; 2013 Jun; 334(1):101-8. PubMed ID: 22935676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA-seq reveals novel cancer-selective and disease subtype-independent mechanistic targets of withaferin A in human breast cancer cells.
    Hahm ER; Kim SH; Singh KB; Singh SV
    Mol Carcinog; 2021 Jan; 60(1):3-14. PubMed ID: 33150660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
    Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
    Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
    Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
    Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of a novel ataxia-telangiectasia mutated and Rad3 related/checkpoint kinase 1-dependent prometaphase checkpoint in cancer cells by diallyl trisulfide, a promising cancer chemopreventive constituent of processed garlic.
    Herman-Antosiewicz A; Stan SD; Hahm ER; Xiao D; Singh SV
    Mol Cancer Ther; 2007 Apr; 6(4):1249-61. PubMed ID: 17406033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.
    O'Flanagan CH; O'Shea S; Lyons A; Fogarty FM; McCabe N; Kennedy RD; O'Connor R
    Oncotarget; 2016 Aug; 7(35):56826-56841. PubMed ID: 27472395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
    Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.
    Samanta SK; Sehrawat A; Kim SH; Hahm ER; Shuai Y; Roy R; Pore SK; Singh KB; Christner SM; Beumer JH; Davidson NE; Singh SV
    J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28040797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors.
    Singh KB; Hahm ER; Kim SH; Singh SV
    Cancer Prev Res (Phila); 2023 Jan; 16(1):5-16. PubMed ID: 36251722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
    Zheng H; Shao F; Martin S; Xu X; Deng CX
    Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells.
    Szarc vel Szic K; Op de Beeck K; Ratman D; Wouters A; Beck IM; Declerck K; Heyninck K; Fransen E; Bracke M; De Bosscher K; Lardon F; Van Camp G; Vanden Berghe W
    PLoS One; 2014; 9(2):e87850. PubMed ID: 24498382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells.
    Xia S; Miao Y; Liu S
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2363-2369. PubMed ID: 29966656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells.
    Kim SH; Singh SV
    Cancer Prev Res (Phila); 2014 Jul; 7(7):738-47. PubMed ID: 24824039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
    Tyagi A; Singh RP; Agarwal C; Siriwardana S; Sclafani RA; Agarwal R
    Carcinogenesis; 2005 Nov; 26(11):1978-87. PubMed ID: 15975956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B.
    Kim H; Cho U; Hong SH; Park HS; Kim IH; An HJ; Shim BY; Kang JH
    Oncol Res; 2024; 32(6):1021-1030. PubMed ID: 38827321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.
    Abdel-Fatah TM; Middleton FK; Arora A; Agarwal D; Chen T; Moseley PM; Perry C; Doherty R; Chan S; Green AR; Rakha E; Ball G; Ellis IO; Curtin NJ; Madhusudan S
    Mol Oncol; 2015 Mar; 9(3):569-85. PubMed ID: 25468710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
    Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.